Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

April 16, 2019

Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers - San Diego, April 16, 2019 – Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Read More

Events

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

April 18, 2019

Join our CEO, Dr. Ivor Royston, for a Rady School guest lecture on “Fostering Medical Innovation: Reflections from an Academic Physician, Entrepreneur, Venture Capitalist, and Biotech CEO”. Read More

Recent News

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

April 16, 2019

Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers - San Diego, April 16, 2019 – Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Read More

Events

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

April 18, 2019

Join our CEO, Dr. Ivor Royston, for a Rady School guest lecture on “Fostering Medical Innovation: Reflections from an Academic Physician, Entrepreneur, Venture Capitalist, and Biotech CEO”. Read More